Elon Musk ‘Takes Ketamine to Manage Depression’, Report Says
Elon Musk takes ketamine in small doses to treat depression and uses higher doses of the drug at social occasions, according to The Wall Street Journal.
Author: Maria Holyanova
The FDA Issues Guidance on Designing Psychedelic Clinical Trials
The Food and Drug Administration published a new draft guidance with the purpose to advise researchers on study design when investigating the potential of psychedelics.
Inside Ibogaine: The Overlooked Yet Promising Psychedelic for Addiction Recovery
Ibogaine’s anti-addictive properties are known to work wonders on people struggling with various substances, such as cocaine, amphetamines, alcohol, nicotine and more.
Ayahuasca May Have Aided in the Rescue of Children Lost in the Amazon Forest
Ayahuasca may have aided in finding four children lost in the Amazon jungle, following a deadly plane crush.
Canadian Study Uncovers Significant Reductions in Substance Use After Psychedelics
A Canadian study found significant reductions in substance use after taking psychedelics, including alcohol and cocaine.
Montreal’s First Shroom Dispensary Is Set to Open in Less Than Three Weeks
FunGuyz, an Ontario shroom shop chain, will open two new shroom dispensaries in Montreal this summer as part of its expansion.
Healing for All: Warriors of Consciousness Making Ketamine Therapy Accessible
Warriors of Consciousness helps individuals struggling with anxiety, PTSD and depression to get access to free ketamine therapy.
Psychedelic Users Show Greater Psychological Strengths and Improved Well-being, Study Finds
A new study published in the International Journal of Wellbeing, found that classical psychedelic users have “greater psychological strengths and well-being, and lower levels of distress” compared to cannabis and alcohol.
The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off
The largest Phase 3 clinical trial investigating the efficacy and tolerability of psilocybin for treatment-resistant depression (TRD) has finally begun.
Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer Patients
A single 25mg dose of psilocybin paired with psychological support has resulted in 57% of patients.
End of content
End of content